Generic Name and Formulations:
Butalbital 50mg, acetaminophen 325mg; tabs.
Various generic manufacturers
- FDA Approves Avelumab for Urothelial Carcinoma
- Rapid Rituximab Administration Safe for Primary CNS Lymphoma
- FDA Approves Elotuzumab for Relapsed, Refractory Multiple Myeloma
- Migraine and Headache Treatments
- Potentially Inappropriate Drugs for the Elderly (Beers List)
- Common Medical Abbreviations
Indications for Butalbital/Acetaminophen:
Tension (or muscle contraction) headache.
1–2 tabs every 4 hours; max 6 tabs daily.
Extended use: not recommended. Severe renal or hepatic impairment. Acute abdominal conditions. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiated by alcohol, other CNS depressants, MAOIs. May cause false (+) urine test for 5-hydroxyindoleacetic acid.
Barbiturate + analgesic.
Drowsiness, dizziness, paradoxical excitement, rash; overdosage: respiratory depression, hepatotoxicity.
Formerly known under the brand name Phrenilin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy